Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOYAGER Study of early nivolumab induction therapy for advanced gastric cancer
jRCTs071190025Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Bristol Myers Squibb. Primary endpoint: 6-month progression-free survival rate. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs071190025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190025.